Market closed
Rhythm Pharmaceuticals/$RYTM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Ticker
$RYTM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
226
Website
RYTM Metrics
BasicAdvanced
$3.5B
-
-$4.33
2.09
-
Price and volume
Market cap
$3.5B
Beta
2.09
52-week high
$65.17
52-week low
$35.17
Average daily volume
454K
Financial strength
Current ratio
3.487
Quick ratio
3.255
Long term debt to equity
74.181
Total debt to equity
74.181
Interest coverage (TTM)
-13.47%
Management effectiveness
Return on assets (TTM)
-46.24%
Return on equity (TTM)
-147.90%
Valuation
Price to revenue (TTM)
30.993
Price to book
316.3
Price to tangible book (TTM)
734.9
Price to free cash flow (TTM)
-21.148
Growth
Revenue change (TTM)
81.55%
Earnings per share change (TTM)
32.93%
3-year revenue growth (CAGR)
338.24%
3-year earnings per share growth (CAGR)
49.92%
What the Analysts think about RYTM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
RYTM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RYTM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RYTM News
AllArticlesVideos
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
GlobeNewsWire·1 week ago
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
GlobeNewsWire·1 month ago
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $3.5B as of February 22, 2025.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of February 22, 2025.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of February 22, 2025.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.